Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.44 |
| ▸ | QPCT | Q16769 | 4/20 | 0.43 |
| ▸ | CLK1 | P49759 | 7/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538625 | 0.82 | IP6K1 (0.63) | NTRK1IP6K1NTRK3NTRK2QPCT | |
| SCHEMBL2540200 | 0.80 | RAB9A (0.54) | IP6K1QPCTPOLBSMN1; SMN2 | |
| SCHEMBL2538614 | 0.80 | NPC1 (0.56) | IP6K1QPCTPOLBHTTSMN1; SMN2 | |
| SCHEMBL2539436 | 0.78 | MAPT (0.56) | NTRK1IP6K1NTRK3NTRK2QPCT | |
| SCHEMBL2536231 | 0.77 | QPCT (0.67) | NTRK1IP6K1NTRK3NTRK2QPCT | |
| SCHEMBL2543223 | 0.77 | IP6K1 (0.47) | NTRK1IP6K1QPCT | |
| SCHEMBL2545578 | 0.77 | INSR (0.50) | IP6K1QPCT | |
| SCHEMBL2545579 | 0.77 | RAB9A (0.55) | IP6K1QPCTHTTSMN1; SMN2 | |
| SCHEMBL2543317 | 0.77 | KMT2A (0.58) | IP6K1QPCTHTTSMN1; SMN2 | |
| SCHEMBL2544226 | 0.77 | IP6K1 (0.36) | NTRK1IP6K1QPCTPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | NTRK1 4129/4885IP6K1 2750/4885NTRK3 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.